Targeting oncogenic KRasG13C with nucleotide-based covalent inhibitors
L. Goebel, T. Kirschner, S. Koska, A. Rai, P. Janning, S. Maffini, H. Vatheuer, P. Czodrowski, R. S. Goody, M. P. Mueller, D. Rauh
This study designs and evaluates nucleotide-based covalent inhibitors for KRasG13C, showing they block nucleotide exchange and oncogenic signaling.
bioRxiv · Jul 25, 2022Cancer Biology